Contact-Level ABM: Targeting the Key Individuals Within Accounts 

Most ABM programs target accounts. The best ABM programs target people.

This distinction sounds subtle, but its commercial implications are significant. Account-level targeting — serving ads to all employees at a specified set of companies — is a meaningful improvement over broadcasting to the open market. But it still leaves a gap between the audience your budget is reaching and the audience that actually matters for a deal. Contact-level ABM closes that gap.

This post explains what contact-level ABM is, why it represents a genuine upgrade in precision over standard account-level targeting, and which tools are enabling it in B2B life sciences today.

The Limitation of Account-Level Targeting

When a standard ABM program runs programmatic display advertising to a target account list, the targeting mechanism works at the domain or IP address level. The platform identifies devices associated with the target company's network and serves ads to them. In practice, this means your ads are being seen by a broad cross-section of that organization — finance staff, HR, IT, facilities, legal — the vast majority of whom have no relevance to your solution.

Even layering in title or function targeting on LinkedIn, which significantly improves precision, is an approximation. Targeting "Senior Directors and above in Clinical Operations at your target account list" will reach a useful audience, but it will also include people adjacent to the buying committee, exclude buying committee members with non-standard titles, and provide no visibility into which specific individuals are engaging.

Therefore, if you know specific people to target at an account, using broad level account targeting is inefficient. You end up with significant ad spend reaching large numbers of people who will never influence a purchasing decision, while the specific individuals who will are reached only intermittently and without the individual-level visibility that would make outreach actionable.

Account-level targeting is not without value — it builds brand familiarity across an organization, which has genuine commercial benefit. But for the highest-priority accounts and personas, it limits the ability to prioritize getting in front of the right people.

What Contact-Level ABM Does Differently

Contact-level ABM operates from a fundamentally different starting point: instead of targeting a domain or an IP range, it targets a curated list of specific, named individuals.

Using email addresses, names, or device ID matching, contact-level ABM platforms serve ads directly to identified individuals — the exact people you have determined are most likely to be members of the buying committee at your target accounts. Your budget in contact-level ABM is spent almost entirely on those specific people, rather than on the broader organizational population.

The precision has two important consequences.

First, efficiency improves dramatically. When your advertising reaches a list of 200 named individuals across 40 target accounts - those most likely to be part of buying groups - every impression has much higher relevance. There is limited waste of the kind built into account-level programmatic targeting.

Second, and more importantly for the commercial team, the engagement data becomes individually actionable. In account-level ABM, you might know that three people at a target biotech have clicked on your ads this month — but you may not know who they are, what their roles are, or whether they may be part of an-market buying group. In contact-level ABM, you know that the VP of Translational Medicine clicked twice, the Clinical Program Director clicked four times and visited the content page, and the Head of Procurement opened the email sequence. That is a buying committee picture, not an account-level signal — and it significantly changes how the sales team is empowered to engage with a target account.

How Contact-Level Targeting Works

Contact-level ABM platforms work by matching the contacts on your list to real, observable individuals as they browse the web. When a contact on your list visits a property within the platform's publisher network, the platform recognizes them — through email address matching, device ID resolution, or identity graph lookups — and serves your ad to that specific person. The matching happens behind the scenes; from the contact's perspective, they simply see a relevant ad while going about their normal browsing behavior.

Because recognition and serving happen at the individual level, the engagement data the platform returns is correspondingly granular. Marketers and SDRs can see, for each specific contact, how many impressions they received, which ads they engaged with, what content they interacted with downstream, and how their engagement has trended over time. That individual-level record is what makes contact-level ABM commercially actionable in a way that account-level targeting cannot match.

The practical implication for the sales team is significant. Instead of receiving a notification that "someone at Acme Biotech has been active this week" and having to investigate who that might be, the SDR receives a ranked list of named individuals — with titles, content histories, and engagement frequencies — that tells them precisely who to call, in what order, and what to reference when they do. The quality of that first outreach conversation improves substantially when it can open with specific relevance rather than a generic pitch.

Contact-level platforms also integrate with CRM and marketing automation systems, meaning engagement signals flow automatically into the tools the commercial team is already using. A contact who crosses a defined engagement threshold can trigger an SDR task, a lead score update, or an account elevation — without requiring manual review of campaign data. The system surfaces the signal; the team acts on it.

Building the Right Contact List: Where the Real Work Happens

Contact-level targeting is only as powerful as the list it operates from. Precision targeting of the wrong people produces precise data about irrelevant engagement. The effort invested in constructing a high-quality contact list is what determines whether a contact-level ABM program generates genuine commercial intelligence or merely impressive-looking metrics.

In life sciences, building that list well requires assembling intelligence from several distinct sources and using each to inform the others.

1. Start with Life-Science-Specific Intent Signals to Identify the Right Accounts

Before identifying specific contacts, the first question is: which accounts are most likely to be in an active buying cycle right now? In life sciences, the answer comes not from keyword-based web intent data — the signal type that general-purpose ABM platforms are built around — but from events that are predictive of near-term purchasing need.

A new clinical trial registration indicates that a specific program is advancing and that buying groups are likely forming around the services and capabilities needed to execute it. An IND filing signals that a program is preparing for first-in-human work, with all the operational and scientific purchasing that entails. A Series C or D funding round almost always precedes acceleration of program investment and vendor engagement. A regulatory designation — Fast Track, Breakthrough Therapy, Orphan Drug — compresses timelines and creates urgent purchasing needs. A new partnership or licensing deal may bring capital and new program activity simultaneously.

These events are publicly available and systematically trackable through clinical trial registries, regulatory submission databases, SEC filings, and life-science-specific pipeline intelligence platforms. Organizations that build their target account lists from these signals — rather than from generic web intent data — are starting from a fundamentally stronger intelligence position. The accounts they target are not just companies that look like good fits on paper; they are companies with a demonstrable, time-stamped reason to be in-market for a relevant solution.

2. Map the Right Personas for Each Account Type

With a target account list grounded in life-science-specific intent, the next step is determining which individuals within those accounts belong on the contact list. This is where persona mapping does its most important work.

A well-constructed persona map for a given ICP segment documents the titles, functions, and seniority levels that typically appear on the buying committee for that type of purchase. It is built from commercial experience — the sales and BD team's accumulated knowledge of who is actually present when deals of a given type get evaluated and closed — and validated against known patterns in the target account type.

The persona map translates directly into search criteria: when using a contact database to find individuals at a target account, you are looking for the specific titles and functions identified in the persona map. A precise persona map produces a precise contact list. A vague one — "senior people in clinical" — produces a list that is too broad to be useful for contact-level targeting.

The persona map should also be differentiated by account type. The buying committee for a large pharma account and the buying committee for a Series B biotech may share some common roles but differ significantly in seniority, organizational structure, and the degree to which functions are centralized or distributed across programs.

3. Use Contact Databases to Find the Named Individuals

With target accounts identified through intent signals and target personas defined through the persona map, the final step in list construction is finding the specific named individuals who hold those roles at those accounts.

B2B contact databases — platforms that aggregate professional profile data including name, title, employer, email address, and seniority level — are the primary tool for this work. For life sciences, databases with strong coverage of the biotech and pharma sectors, regularly refreshed to account for the high rate of organizational change in this industry, are essential. A contact list built from data that is twelve months out of date in an environment where companies routinely restructure, merge, or reduce headcount is a list that will underperform.

The database search takes the persona map as its input and returns a set of matching individuals at each target account. That set is then cross-referenced with CRM contacts — elevating anyone the commercial team has already engaged — and supplemented with prior campaign engagement data and sales team intelligence from conferences and prior business development activity.

The resulting contact list is not a generic prospecting database. It is a curated set of individuals who work at accounts with documented reasons to be in-market, in roles that correspond to the buying committee for your specific solution type. That specificity is what makes contact-level ABM generate the kind of engagement data that actually moves pipeline.

The shift from lead-based marketing to account-based marketing was a meaningful evolution. Instead of chasing individual contacts and hoping the right person would eventually surface, ABM focused commercial resources on a defined set of high-value organizations, and measured success at the account level rather than the lead level.

But account-level thinking alone is not the complete picture. An account is not a buyer. A buying committee is.

The most sophisticated B2B marketing programs have taken a further step: targeting not just accounts, but the specific groups of individuals within those accounts who are collectively responsible for a purchase decision. Understanding who those people are, what each of them needs to see before they will advocate for your solution, and how to reach all of them simultaneously is what separates ABM programs that generate real pipeline from those that generate account-level engagement without commercial traction.

This post explains the buying committee reality in B2B life sciences, how ABM can be used to surface and engage every relevant stakeholder, and how the pattern of engagement across a buying group becomes one of the most valuable signals in the entire commercial program.

Why Targeting Accounts Is Necessary but Not Sufficient

When a B2B life science company runs an ABM campaign targeting a specific biotech account, it typically generates engagement from some individuals at that company. An ad gets clicked. A white paper gets downloaded. A webinar registration comes in. These are positive signals, but on their own they tell an incomplete story.

The critical question is not just whether someone at the account is engaging. It is whether the right people at the account are engaging — and whether enough of them are engaging simultaneously to indicate that a purchase decision is being considered.

In most B2B life science purchases, a single engaged contact is rarely sufficient to move a deal forward. The purchasing process involves multiple stakeholders, each with a distinct perspective and a distinct set of concerns. A scientist who loves your technology cannot unilaterally approve a contract. A procurement manager who sees your pricing as competitive cannot evaluate your technical capabilities. Each member of the buying committee holds a piece of the decision — and failing to engage all of them means the deal can stall or die even when the initial interest is genuine.

This is the gap that committee-level targeting is designed to close.

The Anatomy of a Life Science Buying Committee

Buying committees in B2B life sciences vary by organization size, outsourcing model, and the nature of what is being purchased. But most purchase decisions of meaningful size involve some combination of the following personas:

The Scientific End-User: the researcher, scientist, or clinical specialist who will actually use the solution. This person cares primarily about technical performance, methodological fit, and whether the solution will work for their specific application. Their endorsement is typically a prerequisite for any serious vendor evaluation.

The Program or Project Lead: the Clinical Program Director, Principal Investigator, or Head of Development for the specific program driving the purchasing need. This person cares about timelines, deliverables, and whether the vendor can reliably execute against the program milestones. They often function as the internal champion if the scientific case is strong.

The Procurement or Vendor Management Function: responsible for vendor qualification, contract terms, pricing, and compliance with the organization's purchasing policies. This persona is often invisible in early-stage engagement and becomes critical — and potentially obstructive — later in the process if not engaged proactively.

The Finance or Budget Holder: particularly relevant for larger contracts or early-stage biotechs where capital allocation decisions are made at a senior level. For mid-size and large biotech pharma, the budget approval process may be separated from the technical selection process.

The Legal and Regulatory Function: for purchases with regulatory or IP implications (which is a large proportion of life science vendor relationships), legal and regulatory affairs team members may need to review and approve vendor agreements.

The C-Suite or Senior Leadership: for strategic vendor relationships, preferred provider agreements, or contracts representing a significant portion of the organization's budget, executive-level buy-in is often required. Even when executives are not part of the day-to-day evaluation, their awareness and support is frequently necessary to close a deal.

The practical implication is that a marketing program focused exclusively on the scientific end-user — the most natural audience for technically-oriented content marketing — is engaging only one member of a committee that may include five or more distinct decision-makers. ABM creates the framework to reach all of them.

How ABM Surfaces the Buying Committee

Identifying who is on the buying committee at a specific target account requires both proactive list-building and reactive signal-reading.

Proactive persona mapping starts with your ICP and the buying committee profiles documented for each ICP segment. For a given account, the commercial team uses contact databases and LinkedIn to identify the individuals at that company who hold the titles and roles corresponding to each buying committee persona. These individuals become the named contacts in the contact-level targeting list for that account — the specific people to whom ads will be served, SDR outreach will be directed, and webinar invitations will be sent.

Reactive signal-reading is equally important. Not every buying committee member will be visible in advance. Some are identified only when they begin engaging with campaign content — a new title downloading a gated white paper, a different persona registering for a webinar, an unfamiliar name clicking through from a LinkedIn ad. Each new engagement from a previously unknown contact at a target account is a data point that refines and expands the picture of who the buying committee may include.

Contact-level ABM platforms — Influ2 and Propensity are platforms which enable contact-level targeting and individual-level visibility. Rather than knowing only that someone at a target account engaged, marketers can see precisely which person engaged, with what content, and how many times. When three individuals with different titles — a Biomarker Scientist, a Clinical Program Director, and a Procurement Manager — from the same mid-size biotech all interact with relevant content within a two-week window, this is a strong indication of possible  buying-committee level interest. That account should be elevated immediately in scoring and flagged for targeted sales outreach.

Deploying Content That Speaks to Each Persona

Identifying the buying committee is a key step, and one which is enabled by tailored content. Engaging each member of a buying committee effectively requires content and messaging calibrated to each persona's specific concerns — not a single piece of content served to everyone.

This is where the content matrix becomes an essential planning tool. A content matrix maps each buying committee persona to the content types and messages most likely to resonate with them at each stage of the funnel. What it produces in practice is a set of parallel tracks — each targeting a different member of the committee with content relevant to their role — that together build consensus across the full group.

For the scientific end-user, the most effective content is technically substantive: application notes, analytical validation data, peer-reviewed publications, detailed methodology comparisons. This audience wants to see evidence that the solution works and that the team behind it understands the science.

For the program lead, the relevant content shifts toward execution and outcomes: case studies documenting successful program delivery, data on timelines met and milestones achieved, testimonials from peers who have navigated similar program challenges. They need to be confident that the vendor will deliver.

For procurement and finance, the relevant content addresses risk management, vendor qualification, and commercial terms: quality system documentation, regulatory compliance credentials, contract flexibility, pricing transparency, and reference client information.

For senior leadership, the appropriate content is strategic: thought leadership on sector trends, evidence of the vendor's market position and reputation, and any data that positions the relationship as strategically valuable rather than merely transactional.

Running these parallel content tracks through ABM channels — LinkedIn ads targeted by title, contact-level ads to named individuals, email sequences to CRM contacts — means that every member of the buying committee is receiving relevant, role-specific content. This is how consensus is built before the formal vendor evaluation even begins.

A Content Matrix with Examples of Relevant Content by Persona and Engagement Stage

The Pattern of Engagement Is the Signal

The ultimate value of committee-level targeting in ABM is not just that it reaches more people at a target account. It is that the pattern of who is engaging, with what content, and over what timeframe, becomes a reliable indicator of purchase intent.

A single engaged contact might represent genuine interest — or it might represent a researcher doing background reading with no near-term purchasing intent. But when engagement begins to appear across multiple personas at the same account, spanning scientific, operational, and commercial functions, the probability that a buying group is actively evaluating shifts dramatically. The breadth of engagement is the signal.

This is why committee-level visibility changes the nature of the marketing and sales handoff. Instead of passing individual leads to the SDR team and leaving them to figure out whether a deal opportunity exists, a well-instrumented ABM program hands off a picture of the buying committee: which specific individuals have engaged, with which content, and how their engagement maps to the personas typically present when a deal closes. That intelligence turns a cold outreach sequence into a precisely targeted, contextually informed commercial conversation.

The Bottom Line

Targeting accounts is necessary. Targeting buying committees is what makes ABM commercially productive.

The investment required to get there — persona mapping, contact-level targeting infrastructure, parallel content tracks by persona, and the organizational discipline to act on engagement signals quickly — is not trivial. But it is what separates ABM programs that generate genuine pipeline from those that generate engagement data with no clear path to revenue.

In B2B life sciences, where purchasing decisions involve multiple stakeholders and carry real consequences for the programs that depend on them, the ability to surround the full buying committee with relevant, credible, role-specific content before the evaluation formally begins is one of the most durable competitive advantages available.

‍

Account-Based Marketing was not invented for the life sciences. It was developed primarily in the B2B technology sector, refined by SaaS companies selling software to enterprise buyers, and packaged into platforms built to serve that context. The intent data that powers most ABM platforms is calibrated to detect when a company is researching a new CRM, evaluating a cybersecurity vendor, or exploring cloud infrastructure options.

Life science companies that approach ABM by simply adopting the SaaS playbook — the same tools, the same intent signals, the same targeting logic — consistently find that the program underperforms. Not because ABM doesn't work in life sciences. Quite the opposite. ABM is arguably more naturally suited to life science commercial environments than to any other B2B sector. But realizing that potential requires understanding what makes life science buyers different, and adapting the approach accordingly.

This post makes the case for why ABM and life sciences are a particularly strong fit — and why the standard tools and playbooks built for tech markets need meaningful adaptation to work in this one.

The Life Science Buyer Is Unlike Any Other B2B Buyer

Before discussing what makes ABM effective in life sciences, it is worth being precise about what makes life science buyers distinctive. Two characteristics stand out above all others.

Scientific skepticism. Life science professionals — whether Principal Scientists, Clinical Program Directors, or VPs of Research — are trained to evaluate evidence. Their entire professional formation is built around the careful assessment of data quality, methodology, and reproducibility. When they encounter marketing, they apply the same analytical lens. Promotional claims without supporting evidence are dismissed. Vendor messaging that is generic, technically shallow, or obviously optimized for persuasion rather than information is tuned out.

This means that the content-driven approach central to ABM — deploying technically substantive, expertise-demonstrating content to engage target personas — is not just a nice-to-have in life sciences. It is the only category of marketing that this audience will meaningfully engage with. White papers grounded in real data, case studies documenting actual clinical or analytical outcomes, webinars led by genuine subject matter experts, technical guides that help scientists solve real problems — these are the currency of life science engagement. ABM provides the framework for deploying that content with precision to the right audience at the right time.

Purchasing conservatism. Life science purchase decisions are not made quickly, and they are not made lightly. The consequences of a poor vendor selection can be significant: a failed assay that delays a clinical trial, a manufacturing partner whose process fails to scale, a CRO whose regulatory expertise proves insufficient at the NDA stage. Vendors are evaluated not just on capability but on track record, regulatory rigor, quality systems, and the depth of the relationship they are willing to build.

This purchasing dynamic plays directly to ABM's structural strengths. ABM is designed for long sales cycles with multiple decision-makers. Its emphasis on nurturing every member of the buying committee over an extended period — building familiarity and credibility across the full group before a formal evaluation begins — aligns precisely with how life science buyers actually make decisions. The companies that are already known, trusted, and perceived as experts when a buying process formally begins have an enormous advantage. ABM is the systematic approach to building that position.

Life Science Accounts Often Contain Multiple Independent Buying Groups

Beyond buyer psychology, life science organizations have a structural characteristic that makes ABM particularly valuable: within a single account, there are often multiple distinct buying groups, each tied to a different program, trial, or research initiative, each with its own decision-makers, timeline, and purchasing needs.

A mid-size biopharmaceutical company running four clinical programs might have a buying group forming around a Phase 2 biomarker program, a separate group evaluating outsourced manufacturing for a Phase 3 asset, and a third group assessing clinical data management solutions for a new trial filing. These three groups share an employer but not a budget, not a decision-making process, and not a set of needs.

In a traditional lead-generation model, engagement from any employee at this company would be pooled into a single account record — and the commercial team would often have no clear picture of which program was generating interest, who the relevant stakeholders were, or which opportunity was most sales-ready. ABM — particularly contact-level ABM using platforms like Influ2 or Propensity — enables a different approach: identifying which individuals at the account are engaging, what content they are engaging with, and therefore which buying group is forming around a specific need. That granularity transforms an ambiguous account into a specific, actionable opportunity.

This reality also means that a single target account in life sciences can yield multiple distinct commercial opportunities over time. An ABM program that successfully engages the first buying group, delivers a strong outcome, and builds a genuine relationship within that account is positioned to identify and engage the next buying group as a new program advances. In life sciences, account depth — the degree to which a vendor is embedded across multiple programs and buying groups within a strategic account — is one of the most important drivers of long-term revenue. ABM is the framework for building it.

Why Standard ABM Tools Miss the Mark in Life Sciences

If ABM is so well-suited to life sciences, why do so many life science companies find that off-the-shelf ABM platforms underdeliver?

The answer lies primarily in intent data. Widely-used tools for determining “intent” and finding in-market accounts like 6Sense and Bombora build their intent models around web search behavior and content consumption patterns detected through publisher networks. These signals are effective at identifying when a company is actively researching a specific category of B2B software: an unusual volume of employees visiting competitor websites, searching industry-specific keywords, or reading relevant analyst reports.

In life sciences, this kind of keyword-based, web-behavior intent data captures only a fraction of the signals that actually predict purchasing intent. The most valuable in-market signals in this sector are explicit, publicly available events that standard ABM platforms are not designed to monitor:

A new funding round — a Series B, C, or D, an IPO, or a significant partnership or licensing deal — almost always triggers program advancement and the engagement of new or expanded vendor relationships. A biotech that just closed a $150M Series C to advance its lead oncology asset into Phase 2 is a highly actionable target. Standard ABM platforms will not surface this signal unless the company coincidentally happens to be searching relevant keywords at the same time.

A clinical trial filing — signals that a specific program is advancing and that a buying group is likely forming around the services and capabilities needed to execute it. These filings are public and structured, but they are not indexed by standard ABM intent platforms.

A regulatory milestone — a Fast Track designation, a Breakthrough Therapy designation, an NDA filing — compresses timelines and creates urgent purchasing needs around the capabilities required to reach or respond to that milestone. These events are highly predictable in their commercial implications, but invisible to standard intent platforms.

Similarly, grant awards in the academic and government research sector — NIH R01s, BARDA contracts, DoD funding — are among the clearest intent signals for vendors serving this segment, and are entirely absent from conventional ABM intent data.

Life science-specific data platforms that aggregate clinical trial registries, funding databases, regulatory filings, pipeline intelligence, and grant award data provide a categorically different quality of intent signal for this sector. Overlaying keyword-based web intent data on top of these signals creates a layered picture of in-market accounts that is far more actionable than either source alone. This is a critical adaptation — and one that requires deliberate attention when building or evaluating a life science ABM program.

The Takeaway

ABM works in life sciences not because it is a clever tactic, but because the structure of the approach maps almost perfectly onto the realities of the market: long sales cycles, conservative buyers, technically demanding audiences, complex multi-stakeholder purchasing processes, and accounts that contain multiple distinct commercial opportunities simultaneously.

What requires adaptation is not the strategic logic of ABM, but the specific tools and data sources used to execute it. Generic intent signals, tech-focused platforms, and SaaS-derived playbooks need to be replaced or supplemented with life-science-specific data intelligence, modality and pipeline-aware targeting, and content strategies calibrated for scientifically trained audiences.

Organizations that make that adaptation — and approach ABM as a life-science-native capability rather than a technology market import — consistently find that it outperforms any other commercial approach available to them.